

CLAIM LISTING

1-20. (Canceled)

21. (Previously presented) An immunologically active chimeric anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6.

22-25. (Canceled)

26. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.

27-41. (Canceled)

42. (Previously presented) A composition comprising a chimeric anti-CD20 antibody according to Claim 21 and a pharmaceutically acceptable buffer.

43-46. (Canceled)

47. (Currently amended) The composition of Claim ~~41 or~~ 42 which is suitable for parenteral administration.

48. (Previously presented) The composition of Claim 47 wherein the parenteral administration is selected from the group consisting of intravenous, intramuscular, vaginal, intraperitoneal, and subcutaneous administration.

49-50. (Canceled)

51. (Currently amended) The composition of Claim ~~41 or~~ 42 which is formulated to deliver an effective dose ranging from about 0.01 to 30 mg/kg body weight upon administration to a patient.
52. (Previously presented) The composition of Claim 51 wherein the dose ranges from about 0.01 to about 25 mg/kg body weight.
53. (Previously presented) The composition of Claim 51 wherein the dose ranges from about 0.4 mg to about 20 mg/kg body weight.
- 54-57. (Canceled)
58. (Previously presented) An isolated anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6.
59. (Previously presented) The anti-CD20 antibody of Claim 58 wherein the antibody is murine.
- 60-69. (Canceled)
70. (Previously presented) A composition comprising an anti-CD20 antibody according to Claim 58 and a pharmaceutically acceptable buffer.
71. (Previously presented) The chimeric antibody of Claim 21 wherein the antibody is not conjugated to a toxin or radioisotope.
72. (Previously presented) The chimeric antibody of Claim 21 wherein the antibody comprises a human light chain kappa constant region and a human heavy chain gamma 1 constant region.